Inhibace Plus

Cilazapril, the active ingredient in Inhibace Plus, is an ACE inhibitor and thiazide diuretic combination presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Inhibace Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inhibace Plus is used to manage high blood pressure by targeting the renin‑angiotensin system and promoting diuresis. - Hypertension: lowers systolic and diastolic pressure through vasodilation and reduced blood volume. - Essential hypertension: provides effective control when monotherapy is insufficient. - Combination therapy hypertension: offers a single‑pill option for patients requiring both an ACE inhibitor and a thiazide diuretic.

Adverse reactions may occur with any antihypertensive combination.

Common Side Effects: - Dizziness or light‑headedness - Headache - Persistent dry cough - Fatigue or weakness - Increased urinary frequency - Mild electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Angioedema or swelling of the face, lips, tongue - Severe dehydration or hypotension - Acute kidney injury or sudden rise in serum creatinine - Hyperkalemia or severe electrolyte imbalance - Blood dyscrasias such as agranulocytosis - Severe allergic reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters. - Renal function: assess serum creatinine and eGFR before and during treatment. - Electrolytes: monitor potassium and sodium levels regularly. - Severe renal impairment: avoid or use with caution. - Diabetes mellitus: watch for changes in blood glucose control. - Pregnancy: safety not established; use only if clearly needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Drug‑drug interactions can modify efficacy or increase toxicity.

Major Interactions (Avoid): - Lithium: risk of lithium toxicity increases. - NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and impair renal function. - Potassium‑sparing diuretics or supplements: can cause dangerous hyperkalemia. - Concurrent ACE inhibitor or ARB therapy: heightened risk of renal impairment and hyperkalemia.

Moderate Interactions (Monitor Closely): - Other diuretics: may exacerbate electrolyte loss; monitor labs. - Antihypertensives (beta‑blockers, calcium channel blockers): additive blood‑pressure lowering; watch for hypotension. - Rifampin or other enzyme inducers: may reduce plasma concentrations of cilazapril.